The French National Research Agency Projects for science

Version franaise


Preliminary announcement : A call for research projects about "Hypothesis-driven use of multi-omic integrated approaches for discovery of disease causes"

Within the framework of the ERA-Net E-Rare-3, the French National Research Agency will launch, in collaboration with 18 countries (Austria, Belgium, Canada, Czech Republic, Finland, France, Germany, Greece, Hungary, Israel, Italy, Latvia, Poland, Romania, Spain, Switzerland, The Netherlands and Turkey) the tenth call for funding multilateral research projects on rare diseases. The call will open on December 7, 2017.

The French National Research Agency will finance solely French partners of selected projects, and for a maximum duration of 3 years.


The aim of the call is to enable scientists in different countries to build an effective collaboration on a common interdisciplinary research project based on complementarities and sharing of expertise, with a clear translational research approach. Projects shall involve a group of rare diseases or a single rare disease following the European definition i.e., a disease affecting not more than five in 10 000 persons in the European Community, EC associated states and Canada.

Call Topic

The specific objective of this call are hypothesis-driven use of multi-omic integrated approaches for discovery of disease causes and/or functional validation in the context of rare diseases.
Transnational research proposals must cover at least one of the following areas, which are equal in relevance for this call:
•    Combined multi-omics approaches (e.g. epigenomics, transcriptomics, metabolomics, proteomics, etc.) that complement genomics-based gene discovery strategies and that are driven by a lead hypothesis
•     Functional validation of clinical or biological inferences obtained from “-omics” results
•    Application of “-omics” approaches to rare diseases for which the gene(s) is/are known to enable insight into disease pathophysiology
•    Development and application of concepts and methods for pathogenic read-outs of disease groups, which can be used as "blue print" to discover new disease genes and inform pathomechanism


(1) therapeutic approaches concerning rare infectious diseases, rare cancers and rare adverse drug events in treatments of common diseases

(2) Interventional clinical trials

General provisions
Only transnational projects will be funded. Each consortium submitting a proposal must involve a minimum of three eligible and a maximum of six eligible partners from at least three different countries participating in the call. Not more than two eligible partners from the same country participating in the call will be accepted in one consortium.
Applicants are encouraged to include partners from the participating Eastern European countries (Czech Republic, Hungary, Latvia, Poland, Romania, Turkey). If they include such partners, the maximum number of partners can be increased to eight.
Additional partners that secure their own funding may join consortia. However, their number is limited to two.

For more detailed information regarding this call, please visit the E-Rare website :


Tentative timetable

•    Opening of the call: December 7, 2017
•    Deadline to submit a pre-proposal : February 6, 2018
•    Deadline to submit the full proposal : June 19, 2018
•    Announcement of results : November 2018
•    Start of funding : beginning of 2019


Email :
Ingrid Pfeifer, PhD
Phone: + 33) (0)1 78 09 80 22
Daria Julkowska, PhD
Phone: + 33) (0)1 78 09 80 78